Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, clear cell renal carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder	Active, not recruiting	Phase 2	2026-06-03		NCT03092856

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
National Cancer Institute (NCI)	3015
University of Southern California	216

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center	Cleveland	United States	20
Los Angeles County-USC Medical Center	Los Angeles	United States	32
University of California Davis Comprehensive Cancer Center	Sacramento	United States	299
University of Kansas Cancer Center	Kansas City	United States	242
University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh	United States	70
University of Virginia Cancer Center	Charlottesville	United States	11
USC / Norris Comprehensive Cancer Center	Los Angeles	United States	249
USC Norris Oncology/Hematology-Newport Beach	Newport Beach	United States	71
Weill Cornell Medical College, New York- Presbyterian Hospital	New York	United States	1